Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
ITCI

ITCI - Intra-Cellular Therapies Inc Stock Price, Fair Value and News

$131.87 
Market Closed

ITCI Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ITCI Price Action

ITCI RSI Chart

ITCI Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ITCI Valuation

ITCI Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ITCI Fundamentals

ITCI Revenue

ITCI Earnings

ITCI Profitability

ITCI Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024513.9M564.5M613.7M680.9M
2023310.6M365.8M420.1M464.4M
2022102.9M138.5M188.1M250.3M
202137.6M55.7M70.6M83.8M
20209.3M13.8M18.3M22.8M
20190004.8M
2017426.0K312.3K338.7K245.8K
20160316.5K263.5K361.4K
20150466.9K247.7K153.9K
20142.3M1.9M1.3M577.3K
20133.1M2.3M2.6M2.7M
2012016.6M9.9M3.1M
201100023.4M
Get all data in R, Python etc through our Historical Stock Data APIs

About Intra-Cellular Therapies Inc

ITCI
Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, heart failure, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
 CEO
 WEBSITEintracellulartherapies.com
 SECTORHealthcare
 INDUSTRYDrug Manufacturers Specialty & Generic
 EMPLOYEES561